SLC5A2 and type 1 diabetes mellitus: As there are currently few regions/countries other than Japan where SGLT2 inhibitors are officially approved for use in T1D populations, the real-world evidence concerning the additional benefits of SGLT2 inhibitors in T1D is limited.